The hospital is using the SOPHiA DDM™ Platform
to advance the research of
Homologous Recombination Repair Mutated
Cancers
BOSTON and ROLLE, Switzerland, Aug. 30,
2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company and a leader in data-driven
medicine, today announced that CHU Bordeaux, a full-service
hospital servicing the population of Bordeaux and the surrounding area, has
completed implementation of the SOPHiA DDM™ Platform into its
organization. The hospital will be using the SOPHiA GENETICS
technology to help advance its research on homologous recombination
repair (HRR) mutated cancers.
HRR is a DNA repair pathway that acts on DNA double-stranded
breaks. Deficiency in HRR (known as HRD) leads to the accumulation
of gene mutations and genomic instability, and is a common feature
of ovarian, breast, prostate, and pancreatic cancers. HRD can also
arise from mutations in a wider set of HRR genes across various
cancer types.1, 2, 3
To detect HRD, researchers often use next-generation
sequencing (NGS), which can produce a complex data set that is
time-intensive and costly to analyze. The SOPHiA DDM™ Platform uses
Artificial Intelligence (AI) and machine learning with patented
technologies to analyze and interpret raw NGS data. The Platform
also provides a unique approach to molecular cancer testing by
combining information from HRR mutations with a measure of genomic
scarring. The SOPHiA DDM™ Platform provides reliable and fast HRD
results that can help guide the team at CHU Bordeaux in generating
data-driven insights.
"Our goal at SOPHiA GENETICS is to help facilitate research and
insights for serious conditions such as cancer to enable the
widespread adoption of precision medicine as the gold standard of
treatment," said Kevin Puylaert, Managing Director, EMEA, SOPHiA
GENETICS. "In line with our goal, customers like CHU Bordeaux that
are dedicated to research and medical innovation are embracing the
foundations for precision medicine by adopting the SOPHiA DDM™
Platform. This will enable the hospital to advance its research on
HRR-mutated tumors and be better informed to make data-driven
decisions."
The SOPHiA DDM™ Platform will help CHU Bordeaux create a more
efficient bioinformatics workflow for accuracy and simplification
where possible when analyzing NGS data. Additionally, with the
SOPHiA DDM™ Platform technology CHU Bordeaux will be able to create
an in-house database from genomics profiles its researchers
analyze.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook,
and Instagram
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains
statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products, and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management's beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
1 Stewart MD, et al. Oncologist.
2022;27(3):167-174
2 Miller RE, et al. Ann Oncol. 2020;31(12):1606-1622
3 Mekonnen N, et al. Front Oncol. 2022;12:880643
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chu-bordeaux-is-live-on-sophia-genetics-301912473.html
SOURCE SOPHiA GENETICS